자간전증 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Preeclampsia Diagnostics Market size is expected to reach USD 6.22 Billion in 2034 from USD 2.50 Billion (2025) growing at a CAGR of 10.66% during 2026-2034.

The Preeclampsia Diagnostics market is poised for significant growth, driven by the increasing prevalence of preeclampsia and the need for timely and accurate diagnostic solutions. Preeclampsia, a pregnancy-related condition characterized by high blood pressure and organ dysfunction, poses serious risks to both maternal and fetal health. As healthcare providers seek to improve outcomes for pregnant women, the demand for innovative diagnostic tools that can identify preeclampsia early is surging. This market encompasses a range of products, including blood pressure monitors, biomarker tests, and imaging technologies that aid in the assessment of preeclampsia risk.

Technological advancements are playing a crucial role in shaping the Preeclampsia Diagnostics market, with innovations in biomarker discovery and point-of-care testing enhancing diagnostic capabilities. The development of novel biomarkers that can predict the onset of preeclampsia is revolutionizing the approach to prenatal care, enabling healthcare providers to implement preventive measures and closely monitor at-risk patients. Additionally, the integration of telehealth solutions is facilitating remote monitoring of pregnant women, ensuring timely interventions when necessary. As the market continues to evolve, companies that prioritize research and development to advance their diagnostic offerings will likely capture a larger share of the growing demand.

Furthermore, the Preeclampsia Diagnostics market is increasingly influenced by regulatory developments and clinical guidelines that promote evidence-based practices in prenatal care. As healthcare systems adopt standardized protocols for the diagnosis and management of preeclampsia, the demand for reliable and validated diagnostic solutions will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel diagnostic approaches and improving existing technologies. As the focus on maternal and fetal health grows, the need for effective preeclampsia diagnostics that can be tailored to individual patient needs will expand, positioning companies that align their offerings with clinical requirements for success in this critical market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Blood Tests
• Urine Analysis
• Others

By Product Type

• Instruments
• Consumables

By End User

• Hospital
• Specialty Clinics
• Diagnostic Centers
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Thermo Fisher Scientific Inc, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company BD, bioMrieux, PerkinElmer, Quidel Corporation, Sera Prognostics, Metabolomic Diagnostics Ltd, Diabetomics Inc, Brahms GmbH, The Progenix Group, Roche Diagnostic

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Blood Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Urine Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Product Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Product Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Product Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Product Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Product Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PREECLAMPSIA DIAGNOSTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 Siemens Healthineers
  • 9.2.4 Abbott Laboratories
  • 9.2.5 Beckman Coulter
  • 9.2.6 Becton, Dickinson And Company (BD)
  • 9.2.7 BioMAfA(C)Rieux
  • 9.2.8 PerkinElmer
  • 9.2.9 Quidel Corporation
  • 9.2.10 Sera Prognostics
  • 9.2.11 Metabolomic Diagnostics Ltd
  • 9.2.12 Diabetomics Inc
  • 9.2.13 Brahms GmbH
  • 9.2.14 The Progenix Group
  • 9.2.15 Roche Diagnostic